BOK Financial Private Wealth Inc. Sells 222 Shares of Edwards Lifesciences Co. (NYSE:EW)

BOK Financial Private Wealth Inc. cut its stake in Edwards Lifesciences Co. (NYSE:EW) by 1.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,098 shares of the medical research company’s stock after selling 222 shares during the period. BOK Financial Private Wealth Inc.’s holdings in Edwards Lifesciences were worth $896,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the stock. Argentarii LLC bought a new stake in Edwards Lifesciences in the 4th quarter valued at $256,000. OFI Invest Asset Management bought a new position in shares of Edwards Lifesciences during the 4th quarter worth about $22,705,000. Bank Julius Baer & Co. Ltd Zurich lifted its holdings in shares of Edwards Lifesciences by 33.5% during the 4th quarter. Bank Julius Baer & Co. Ltd Zurich now owns 127,436 shares of the medical research company’s stock worth $10,411,000 after acquiring an additional 31,972 shares during the period. Aviance Capital Partners LLC lifted its holdings in shares of Edwards Lifesciences by 8.3% during the 4th quarter. Aviance Capital Partners LLC now owns 7,794 shares of the medical research company’s stock worth $577,000 after acquiring an additional 600 shares during the period. Finally, Destination Wealth Management lifted its holdings in shares of Edwards Lifesciences by 12.6% during the 4th quarter. Destination Wealth Management now owns 7,893 shares of the medical research company’s stock worth $584,000 after acquiring an additional 881 shares during the period. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Stock Down 2.0 %

Shares of NYSE EW opened at $70.36 on Friday. The firm has a market capitalization of $41.37 billion, a PE ratio of 10.10, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12. The firm’s 50-day moving average is $72.26 and its 200-day moving average is $70.38.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Equities analysts expect that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Insider Buying and Selling

In related news, VP Daniel J. Lippis sold 500 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the transaction, the vice president now owns 23,189 shares of the company’s stock, valued at $1,594,475.64. This trade represents a 2.11 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total transaction of $852,300.00. Following the transaction, the chief financial officer now directly owns 30,561 shares in the company, valued at $2,315,301.36. The trade was a 26.91 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 37,739 shares of company stock valued at $2,799,104 in the last 90 days. 1.29% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Bank of America raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $82.00 to $90.00 in a report on Monday, December 16th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $85.00 price objective on shares of Edwards Lifesciences in a report on Wednesday, February 12th. Stifel Nicolaus upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and increased their target price for the stock from $75.00 to $90.00 in a research report on Thursday, January 30th. Wolfe Research cut shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 12th. Finally, Truist Financial reiterated a “hold” rating and set a $78.00 target price (up previously from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $79.95.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.